[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334431-105":59,"doc-detail-334431-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-combined-opposite-targeting-of-p110-pi3k-and-rhoa-abrogates-skin-cancer","A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer","","Malignant melanoma and squamous cell carcinoma represent highly aggressive and common non-melanoma skin cancers, yet treatment options remain limited. This study demonstrates that combined opposite targeting of RhoA and p110δ PI3K blocks melanoma and SCC development and metastasis. RhoA activity is induced in tumours via p190RhoGAP deletion together with adoptive macrophage transfer, leading to abrogated growth progression. Efficacy is consistent across tumors with or without activating BRAF mutations, linked to decreased ATX expression and bypass of ATX feedback.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-combined-opposite-targeting-of-p110-pi3k-and-rhoa-abrogates-skin-cancer/334431/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-combined-opposite-targeting-of-p110-pi3k-and-rhoa-abrogates-skin-cancer/334431.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does the combined targeting of RhoA and p110δ PI3K affect skin cancer progression?","Question",{"text":112,"@type":113},"It blocks development and metastasis of both melanoma and SCC by abrogating tumor growth progression when RhoA activity is induced together with macrophage transfer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Does the treatment work for tumors with different BRAF mutation statuses?",{"text":117,"@type":113},"Yes. The combined treatment efficacy is reported to be the same in tumors lacking activating BRAF mutations and those carrying the common BRAF(V600E) mutation.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links the combined therapy to changes in tumor biology?",{"text":121,"@type":113},"The study associates therapeutic efficiency with decreased ATX expression in tumor cells and stroma, bypassing a positive feedback ATX expression triggered by direct ATX pharmacological inactivation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334431,1791101564,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","ARTICLE   \n [https://doi.org/10.1038/s42003-023-05639-8](https://doi.org/10.1038/s42003-023-05639-8)  OPEN  \nA combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer  \nNiki Tzenaki1, Lydia Xenou1, Evangelia Goulielmaki1, Anna Tsapara1, Irene Voudouri1, Angelika Antoniou1, George Valianatos1, Maria Tzardi2, Eelco De Bree3, Aikaterini Berdiaki4, Antonios Makrigiannakis4 & Evangelia A. Papakonstanti  1 ✉  \nMalignant melanoma is the most aggressive and deadly skin cancer with an increasing incidence worldwide whereas SCC is the second most common non-melanoma human skin cancer with limited treatment options. Here we show that the development and metastasis of melanoma and SCC cancers can be blocked by a combined opposite targeting of RhoA and p110δ PI3K. We found that a targeted induction of RhoA activity into tumours by deletion of p190RhoGAP-a potent inhibitor of RhoA GTPase-in tumour cells together with adoptive macrophages transfer from δD910A/D910A mice in mice bearing tumours with active RhoA abrogated growth progression of melanoma and SCC tumours. Τhe efﬁcacy of this combined treatment is the same in tumours lacking activating mutations in BRAF and in tumours harbouring the most frequent BRAF(V600E) mutation. Furthermore, the efﬁciency of this combined treatment is associated with decreased ATX expression in tumour cells and tumour stroma bypassing a positive feedback expression of ATX induced by direct ATX pharmacological inactivation. Together, our ﬁndings highlight the importance of targeting cancer cells and macrophages for skin cancer therapy, emerge a reverse link between ATX and RhoA and illustrate the beneﬁt of p110δ PI3K inhibition as a combinatorial regimen for the treatment of skin cancers.  \n1 Department of Biochemistry, School of Medicine, University of Crete, Heraklion, Greece. 2 Department of Pathology, School of Medicine, University of Crete, University Hospital, Heraklion, Greece. 3 Department of Surgical Oncology, School of Medicine, University of Crete, University Hospital, Heraklion, Greece.  \n4 Department of Obstetrics and Gynaecology, School of Medicine, University of Crete, University Hospital, Heraklion, Greece. ✉ email: [epapak@uoc.gr](epapak@uoc.gr)  \nCOMMUNICATIONS BIOLOGY | (2024)7:26 | [https://doi.org/10.1038/s42003-023-05639-8 |www.nature.com/commsbio](https://doi.org/10.1038/s42003-023-05639-8 |www.nature.com/commsbio) 1  \nSkin cancer is the most common malignancy and includes  \nmelanoma and non-melanoma skin cancers. Malignant  \nmelanoma (MM) is not common cancer however, MM is an aggressive and deadly skin cancer 1 and despite the increase ineffective systemic treatment options for advanced stage or metastatic MM during the last decade, still many patients die from this disease2. Squamous Cell Carcinoma (SCC) is a common non-melanoma skin cancer of the squamous cells, which make up the main part of the epidermis of the skin and is caused by the cumulative lifetime exposure to ultraviolet radiation of the sun3,4. The treatment options for locoregionally advanced or metastatic SCC remain limited5.  \nMM has an immune-related pathogenesis and recently, the intratumoural inﬂammatory microenvironment was considered as a better predictor of survival than the histopathological staging6,7 and as an important tool for potential manipulation and proper monitoring of therapies6,7. Tumour-associated macrophages (TAMs) were found to be the major immune constituent of the MM microenvironment and their levels compared with the other leucocytes contribute toward MM’s prognosis8,9 representing a poor indicator of patients’ outcome. Furthermore, TAMs were found to compose cancer stroma not only in melanomas but also in non-melanoma skin cancers 10 and to signiﬁcantly contribute to disease development11. Cutaneous SCChas been characterised as the most common malignancy in immunosuppressed patients such as patients with chronic lymphocytic leukaemia or solid organ transplant recipients 12–15,","cbCaiu19eJ7lNYz0","https://ap.wps.com/l/cbCaiu19eJ7lNYz0","pdf",3432882,18,"English","# Background and clinical need\n## Roles of melanoma and SCC\n## Immune microenvironment and TAMs\n# Autotaxin–LPA axis in skin cancers\n## ATX expression and LPA functions\n## ATX produced by tumor microenvironment\n# PI3K/Akt/mTOR signaling and therapy resistance\n## Evidence linking PI3K pathway to melanoma and SCC\n## Limitations of BRAF, EGFR and checkpoint approaches\n# Combined therapeutic strategy\n## Opposite targeting of RhoA and p110δ PI3K","[{\"question\":\"How does the combined targeting of RhoA and p110δ PI3K affect skin cancer progression?\",\"answer\":\"It blocks development and metastasis of both melanoma and SCC by abrogating tumor growth progression when RhoA activity is induced together with macrophage transfer.\"},{\"question\":\"Does the treatment work for tumors with different BRAF mutation statuses?\",\"answer\":\"Yes. The combined treatment efficacy is reported to be the same in tumors lacking activating BRAF mutations and those carrying the common BRAF(V600E) mutation.\"},{\"question\":\"What mechanism links the combined therapy to changes in tumor biology?\",\"answer\":\"The study associates therapeutic efficiency with decreased ATX expression in tumor cells and stroma, bypassing a positive feedback ATX expression triggered by direct ATX pharmacological inactivation.\"}]","A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer | PDF",1790006626,45]